浙江诚意药业股份有限公司 关于帕拉米韦注射液获得药品注册证书的公告

Overview - Zhejiang Chengyi Pharmaceutical Co., Ltd. has received the drug registration certificate for Palivizumab injection from the National Medical Products Administration [1][2]. Drug Development and Related Information - Palivizumab injection is indicated for the treatment of influenza A or B [2]. - The drug registration application was formally accepted on March 4, 2024, with a total R&D investment of 6.6968 million yuan as of the announcement date [2]. Market Situation - As of the announcement date, there are 35 manufacturers of Palivizumab injection, including Chengyi Pharmaceutical [2]. - The drug was selected in the 10th batch of national centralized procurement in December 2024, with nine companies winning the bid [2]. - The agreed procurement volume for Palivizumab injection is 249,600 units for the 15ml:0.15g specification, 4,000 units for the 20ml:0.2g specification, and 53,500 units for the 60ml:0.3g specification [2]. - The estimated market sales for Palivizumab injection in public medical institutions in 2024 is approximately 9.5 million yuan [2].